SIBRAFIBAN VS ASPIRIN PROTECTION FROM ISCHEMIC HEART EVENTS

SYMPHONY试验--西布拉非班与阿司匹林对急性冠脉综合征后的缺血性心脏事件产生最大保护--是一项多中心药物试验，比较口服血小板膜糖蛋白IIb/IIIa拮抗剂西布拉非班与阿司匹林预防急性冠脉综合征后患者继发血管事件的疗效。这项研究现已接近招募阶段，下一阶段是第三阶段的双盲研究。

The Symphony Trial- Sibrafiban vs. aspirin to yield maximum protection from ischemic heart events post acute coronary syndromes is a multi-center drug trial comparing the efficacy of Sibrafiban, an oral platelet glycoprotein IIb/IIIa antagonist to aspirin as therapy for the prevention of secondary vascular events in patients after an acute coronary syndrome. This study is now closed to recruitment and the next phase is a phase III double blind study.